TLDR EmCoin signed an MoU with Crypto.com to enhance user access to digital assets and trading tools. The collaboration aims to integrate Crypto.com’s liquidityTLDR EmCoin signed an MoU with Crypto.com to enhance user access to digital assets and trading tools. The collaboration aims to integrate Crypto.com’s liquidity

EmCoin Signs MoU with Crypto.com to Expand Digital Asset Access for UAE Users

TLDR

  • EmCoin signed an MoU with Crypto.com to enhance user access to digital assets and trading tools.
  • The collaboration aims to integrate Crypto.com’s liquidity to offer tighter spreads and better execution.
  • Both firms will ensure all integrations and features align with the UAE’s financial regulations.
  • The partners will explore tokenizing real-world assets using technologies like the Cronos EVM chain.
  • While the roadmap is under development, the companies have not announced a launch date for new features.

Emirates Coin Investment LLC (EmCoin), the UAE’s first SCA-licensed virtual asset platform, has signed a Memorandum of Understanding with Crypto.com to improve user access to global digital asset markets, enhance trading features, and explore tokenization of real-world assets.

Agreement Targets Better Access and Execution for EmCoin Users

EmCoin and Crypto.com will collaborate on platform integrations to improve trading conditions and user experience for digital asset transactions. The companies plan to enable access to more cryptocurrencies with tighter spreads while maintaining regulatory compliance across all features. By using Crypto.com’s global liquidity and infrastructure, EmCoin intends to support faster trade execution for its users.

Both parties will prioritize technological enhancements that align with the UAE’s financial regulations. The focus is on building compliant tools that ensure safe and seamless transactions for EmCoin users. EmCoin’s COO Yasin Arafat stated, “Our focus is on making digital asset holdings easier to access, manage, and move.” He added that Crypto.com’s support would improve the platform’s liquidity to support large trade volumes and enhance execution.

Crypto.com’s President and COO, Eric Anziani, said, “We’re looking forward to seeing how our industry-leading products and deep liquidity can advance the EmCoin user experience.” Both companies plan to finalize the integration roadmap after completing all necessary regulatory checks. They also confirmed plans to introduce more user-friendly trading services across supported assets.

Partnership Explores Tokenization of Real-World Assets

Crypto.com and EmCoin also aim to explore tokenization options for real-world assets using blockchain technology within regulatory limits. The companies may apply Crypto.com’s infrastructure and strategic partner technologies, including Cronos EVM chain, to develop tokenized products. The initiative will remain compliant with SCA guidelines and regional licensing standards.

Both platforms have agreed to evaluate possible use cases based on investor demand and operational feasibility. This includes digital representations of assets that can be traded securely within the EmCoin ecosystem. Crypto.com’s Alain Yacine said, “Collaborating with innovators like EmCoin is key to advancing digital asset adoption in the region.”

Alain Yacine emphasized that shared expertise would help streamline how users engage with virtual assets in a trusted environment. The MoU reflects ongoing efforts by both firms to support the UAE’s ambitions in the regulated digital finance space. Each phase of the collaboration will be evaluated against compliance benchmarks and operational goals. The firms have not yet disclosed a launch timeline for the tokenization pilot or trading enhancements.

The post EmCoin Signs MoU with Crypto.com to Expand Digital Asset Access for UAE Users appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26